Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gene Therapy
Danaher will acquire Aldevron for $9.6 billion
by Rick Mullin
June 26, 2021
| A version of this story appeared in
Volume 99, Issue 24
Danaher, a supplier of health-care and process industry products, has agreed to acquire Aldevron, a supplier of plasmid DNA, messenger RNA, and recombinant proteins used in the manufacture of vaccines and cell and gene therapies, for $9.6 billion. Headquartered in Fargo, North Dakota, Aldevron employs about 600 people. The company plans to more than triple capacity this year by adding an 18,000 m2 facility to its 6,500 m2 operation in Fargo. The seller, the private equity firm EQT, bought a majority interest in Aldevron in 2019.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter